Sanders Morris Harris LLC Buys 34,034 Shares of uniQure (NASDAQ:QURE)

Sanders Morris Harris LLC raised its stake in uniQure (NASDAQ:QURE) by 50.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 102,104 shares of the biotechnology company’s stock after buying an additional 34,034 shares during the quarter. Sanders Morris Harris LLC’s holdings in uniQure were worth $1,803,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. Vanguard Personalized Indexing Management LLC raised its holdings in shares of uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 57.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of uniQure in the fourth quarter valued at approximately $88,000. Geode Capital Management LLC raised its holdings in shares of uniQure by 1.3% in the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after purchasing an additional 6,362 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in uniQure by 14.6% during the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after buying an additional 8,642 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on QURE shares. Royal Bank of Canada boosted their target price on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Leerink Partners boosted their target price on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Guggenheim restated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of uniQure in a report on Tuesday, December 10th. Finally, Cantor Fitzgerald boosted their target price on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.88.

uniQure Stock Performance

Shares of uniQure stock traded up $0.04 during trading on Thursday, reaching $14.03. The company’s stock had a trading volume of 37,041 shares, compared to its average volume of 1,339,829. The business’s 50-day moving average price is $11.83 and its 200-day moving average price is $8.24. The firm has a market cap of $683.86 million, a PE ratio of -2.83 and a beta of 0.41. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Equities analysts forecast that uniQure will post -3.74 earnings per share for the current year.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.74% of the stock is currently owned by company insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.